Search

Your search keyword '"Tabar, V."' showing total 211 results
Start Over Author "Tabar, V."
211 results on '"Tabar, V."'

9. State Estimation in Electric Power Systems Based on Adaptive Neuro-Fuzzy System Considering Load Uncertainty and False Data.

Author

Jirdehi, M. Ahmadi and Tabar, V. Sohrabi

Subjects
ELECTRIC power, VOLTAGE, HEURISTIC, ARTIFICIAL neural networks, ELECTRICAL energy
Abstract

Control center of modern power system utilizes state estimation as an important function. In such structures, voltage phasor of buses is known as state variables that should be determined during operation. To specify the optimal operation of all components, an accurate estimation is required. Hence, various mathematical and heuristic methods can be applied for the mentioned goal. In this paper, an advanced power system state estimator is presented based on the adaptive neuro-fuzzy interface system. Indeed, this estimator uses advantages of both artificial neural networks and fuzzy method simultaneously. To analyze the operation of estimator, various scenarios are proposed including impact of load uncertainty and probability of false data injection as the important issues in the electrical energy networks. In this regard, the capability of false data detection and correction are also evaluated. Moreover, the operation of presented estimator is compared with artificial neural networks and weighted least square estimators. The results show that the adaptive neurofuzzy estimator overcomes the main drawbacks of the conventional methods such as accuracy and complexity as well as it is able to detect and correct the false data more precisely. Simulations are carried out on IEEE 14-bus and 30-bus test systems to demonstrate the effectiveness of the approach. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

10. The vascularization potential of endothelial-like cd105+ glioma stem cells

Author

Xu, R, Wang, R, Vajkoczy, P, and Tabar, V

Subjects
ddc: 610, 610 Medical sciences, Medicine, nervous system diseases
Abstract

Objective: Glomeruloid bodies (GB) encompass a characteristic defining neuropathologic feature in glioblastoma multiforme (GBM). Recent studies have shed light on the role of glioma stem cells (GSC) that can give rise to endothelial and mural-like cells participating in angiogenesis and tumor vasculature.[for full text, please go to the a.m. URL], 69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie

Published
2018
Full Text
View/download PDF

12. OS1.7 Genomic attributes of tumor evolution and treatment response in diffuse glioma

Author

Lin, A L, primary, Jonsson, P, additional, Ogilvie, S, additional, Chavan, S, additional, Nolan, C, additional, Gavrilovic, I, additional, Kaley, T, additional, Grommes, C, additional, Pentsova, E, additional, Diamond, E, additional, Daras, M, additional, Stone, J, additional, DeAngelis, L, additional, Tabar, V, additional, Brennan, C, additional, Young, R J, additional, Rosenblum, M, additional, Taylor, B S, additional, and Mellinghoff, I K, additional

Published
2018
Full Text
View/download PDF

13. Monitoring the molecular consequences of Notch inhibition in glioblastoma during a Phase 1 trial

Author

Xu, R, Shimizu, F, Gutin, P, Tabar, V, and Omuro, A

Subjects
ddc: 610, Notch Inhibition, 610 Medical sciences, Medicine, Glioblastoma, Clinical Trial
Abstract

Objective: Malignant gliomas (MG) are associated with a dismal prognosis. Notch inhibition via the gamma-secretase inhibitor RO2929097 has emerged as a potential therapeutic option based on modulation of the cancer stem cell population (CSC) and a presumed anti-angiogenic role. This proof-of-concept[for full text, please go to the a.m. URL], 67. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 1. Joint Meeting mit der Koreanischen Gesellschaft für Neurochirurgie (KNS)

Published
2016
Full Text
View/download PDF

15. Outcomes After Salvage Reirradiation for Recurrent Meningioma

Author

Lanning, R.M., primary, Chohan, M.O., additional, Ryan, C., additional, Singh, R., additional, Kohutek, Z.A., additional, Ogilvie, S.Q., additional, Cambridge, L., additional, Yamada, Y., additional, Tabar, V., additional, Beal, K., additional, and Gutin, P.H., additional

Published
2015
Full Text
View/download PDF

16. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma

Author

Hicks, M J, primary, Funato, K, additional, Wang, L, additional, Aronowitz, E, additional, Dyke, J P, additional, Ballon, D J, additional, Havlicek, D F, additional, Frenk, E Z, additional, De, B P, additional, Chiuchiolo, M J, additional, Sondhi, D, additional, Hackett, N R, additional, Kaminsky, S M, additional, Tabar, V, additional, and Crystal, R G, additional

Published
2014
Full Text
View/download PDF

20. LAB-STEM CELLS

Author

Kozono, D., primary, Nitta, M., additional, Sampetrean, O., additional, Kimberly, N., additional, Kushwaha, D., additional, Merzon, D., additional, Ligon, K., additional, Zhu, S., additional, Zhu, K., additional, Kim, T. H., additional, Kwon, C.-H., additional, Becher, O., additional, Saya, H., additional, Chen, C. C., additional, Donovan, L. K., additional, Birks, S. M., additional, Bosak, V., additional, Pilkington, G. J., additional, Mao, P., additional, Li, J., additional, Joshi, K., additional, Hu, B., additional, Cheng, S., additional, Sobol, R. W., additional, Nakano, I., additional, Li, M., additional, Hale, J. S., additional, Myers, J. T., additional, Huang, A. Y., additional, Gladson, C., additional, Sloan, A. A., additional, Rich, J. N., additional, Lathia, J. D., additional, Hall, P. E., additional, Gallagher, J., additional, Wu, Q., additional, Venere, M., additional, Levy, E., additional, Rani, M. S., additional, Huang, P., additional, Bae, E., additional, Selfridge, J., additional, Cheng, L., additional, Guvenc, H., additional, McLendon, R. E., additional, Sloan, A. E., additional, Phillips, H., additional, Lai, A., additional, Bredel, M., additional, Bao, S., additional, Hjelmeland, A., additional, Sinyuk, M., additional, Sathyan, P., additional, Hale, J., additional, Zinn, P., additional, Carson, C. T., additional, Naik, U., additional, Majumder, S., additional, Song, L. A., additional, Vasanji, A., additional, Tenley, N., additional, Hjelmeland, A. B., additional, Peruzzi, P., additional, Bronisz, A., additional, Antonio Chiocca, E., additional, Godlewski, J. A., additional, Guryanova, O. A., additional, Fang, X., additional, Christel, H.-M. C., additional, Benito, C., additional, Zoltan, G., additional, Aline, B., additional, Tilman, S., additional, Josephine, B., additional, Carolin, M., additional, Thomas, S., additional, Violaine, G., additional, Unterberg, A., additional, Capilla-Gonzalez, V., additional, Guerrero-Cazares, H., additional, Cebrian-Silla, A., additional, Garcia-Verdugo, J. M., additional, Quinones-Hinojosa, A., additional, Man, J., additional, Shoemake, J., additional, Rich, J., additional, Yu, J., additional, He, X., additional, DiMeco, F., additional, Vescovi, A. L., additional, Heth, J. A., additional, Muraszko, K. M., additional, Fan, X., additional, Nguyen, S. A., additional, Stechishin, O. D., additional, Luchman, H. A., additional, Kelly, J. J., additional, Cairncross, J. G., additional, Weiss, S., additional, Kim, Y., additional, Kim, E., additional, Guryanova, O. O., additional, Hitomi, M., additional, Lathia, J., additional, Serwanski, D., additional, Robert, J., additional, Lee, J., additional, Nishiyama, A., additional, Liu, J. K., additional, Flavahan, W. A., additional, Fernandez, N., additional, Wu, M., additional, Das, S., additional, Bazzoli, E., additional, Pulvirenti, T., additional, Oberstadt, M. C., additional, Perna, F., additional, Boyoung, W., additional, Schultz, N., additional, Huse, J. T., additional, Fomchenko, E. I., additional, Voza, F., additional, Tabar, V., additional, Brennan, C. W., additional, DeAngelis, L. M., additional, Nimer, S. D., additional, Holland, E. C., additional, Squatrito, M., additional, Chen, Y.-H., additional, Gutmann, D. H., additional, Kim, S.-H., additional, Lee, M. K., additional, Chwae, Y.-J., additional, Yoo, B. C., additional, Kim, K.-H., additional, Soeda, A., additional, Hara, A., additional, Iwama, T., additional, Park, D. M., additional, Golebiewska, A., additional, Bougnaud, S., additional, Stieber, D., additional, Brons, N. H., additional, Vallar, L., additional, Hertel, F., additional, Bjerkvig, R., additional, Niclou, S. P., additional, Hamerlik, P., additional, Rasmussen, R., additional, Fricova, D., additional, Jiri, B., additional, Schulte, A., additional, Kathagen, A., additional, Zapf, S., additional, Meissner, H., additional, Phillips, H. S., additional, Westphal, M., additional, Lamszus, K., additional, Sanzey, M., additional, Singh, S. K., additional, Vartanian, A., additional, Gumin, J., additional, Sulman, E. P., additional, Lang, F. F., additional, Zadeh, G., additional, Bayin, N. S., additional, Dietrich, A., additional, Abel, T., additional, Chao, M. V., additional, Song, H.-R., additional, Buchholz, C. J., additional, Placantonakis, D., additional, Esencay, M., additional, Zagzag, D., additional, Balyasnikova, I. V., additional, Prasol, M. S., additional, Ferguson, S. D., additional, Ahmed, A. U., additional, Han, Y., additional, Lesniak, M. S., additional, Barish, M. E., additional, Brown, C. E., additional, Herrmann, K., additional, Argalian, S., additional, Gutova, M., additional, Tang, Y., additional, Annala, A., additional, Moats, R. A., additional, Ghoda, L. Y., additional, Aboody, K. S., additional, Gadani, S., additional, Adkins, J., additional, Vsanji, A., additional, McLendon, R., additional, Chenn, A., additional, Park, D., additional, Dictus, C., additional, Friauf, S., additional, Valous, N. A., additional, Grabe, N., additional, Muerle, B., additional, Unterberg, A. W., additional, Herold-Mende, C. C., additional, Lee, H. K., additional, Finniss, S., additional, Buchris, E., additional, Ziv-Av, A., additional, Casacu, S., additional, Xiang, C., additional, Bobbit, K., additional, Rempel, S. A., additional, Mikkelsen, T., additional, Slavin, S., additional, Brodie, C., additional, Woo, D.-H., additional, Oh, Y., additional, Kim, M., additional, Nam, D.-H., additional, Li, Q., additional, Salas, S., additional, Pendleton, C., additional, Wijesekera, O., additional, Chesler, D., additional, Wang, J., additional, Smith, C., additional, Levchenko, A., additional, LaPlant, Q., additional, Pitter, K., additional, Bleau, A.-M., additional, Helmy, K., additional, Werbeck, J., additional, Barrett, L., additional, Shimizu, F., additional, Benezra, R., additional, Holland, E., additional, Chu, Q., additional, Bar, E., additional, Orr, B., additional, Eberhart, C. G., additional, Schmid, R. S., additional, Bash, R. E., additional, Werneke, A. M., additional, White, K. K., additional, Miller, C. R., additional, Agasse, F., additional, Jhaveri, N., additional, Hofman, F. M., additional, Chen, T. C., additional, Natsume, A., additional, Wakabayashi, T., additional, Kondo, Y., additional, Chang, N., additional, Moon, E., additional, Kanai, R., additional, Yip, S., additional, Kimura, A., additional, Tanaka, S., additional, Rheinbay, E., additional, Cahill, D., additional, Curry, W., additional, Mohapatra, G., additional, Iafrate, J., additional, Chi, A., additional, Martuza, R., additional, Rabkin, S., additional, Wakimoto, H., additional, Cusulin, C., additional, Frank, J. A., additional, and Annala, A. J., additional

Published
2012
Full Text
View/download PDF

21. NEUROSURGICAL TREATMENTS

Author

Nanney, A. D., primary, Adel, J. G., additional, Smith, T. R., additional, Chandler, J. P., additional, Kimmell, K. T., additional, Walter, K., additional, Zacharia, B. E., additional, Deibert, C., additional, Malone, H. R., additional, Sonabend, A. M., additional, Neugut, A. I., additional, Spencer, B., additional, Bruce, J. N., additional, Wang, Y., additional, Li, S., additional, Zhang, Z., additional, Chen, X., additional, You, G., additional, Yang, P., additional, Yan, W., additional, Bao, Z., additional, Yao, K., additional, Liu, Y., additional, Wang, L., additional, Jiang, T., additional, Farhoud, M. K., additional, Ruge, M. I., additional, Brandes, A. A., additional, Ermani, M., additional, Fioravanti, A., additional, Andreoli, A., additional, Pozzati, E., additional, Bacci, A., additional, Bartolini, S., additional, Poggi, R., additional, Crisi, G., additional, Franceschi, E., additional, Recinos, P. F., additional, Grabowski, M. M., additional, Nowacki, A. S., additional, Thompson, N., additional, Vogelbaum, M. A., additional, Sun, P., additional, Krueger, D., additional, Liu, Z., additional, Kohrman, M., additional, Dagens, A. B., additional, Rachinger, W., additional, Kunz, M., additional, Eigenbrod, S., additional, Lutz, J., additional, Tonn, J.-C., additional, Kreth, F.-W., additional, Duong, H. T., additional, Chaloner, C., additional, Bordo, G., additional, Eisenberg, A., additional, Rosenthal, K., additional, Sim, M.-S., additional, Boasberg, P., additional, Faries, M. B., additional, Hamid, O., additional, Kelly, D. F., additional, Thon, N., additional, Simon, M., additional, Westphal, M., additional, Schackert, G., additional, Nikkhah, G., additional, Hentschel, B., additional, Pietsch, T., additional, Reifenberger, G., additional, Weller, M., additional, Ironside, S., additional, Perry, J., additional, Tsao, M., additional, Mainprize, T., additional, Keith, J., additional, Laperrierre, N., additional, Paszat, L., additional, Sahgal, A., additional, Hoover, J. M., additional, Nwojo, M., additional, Puffer, R., additional, Parney, I. F., additional, Tanaka, S., additional, Nakada, M., additional, Hayashi, Y., additional, Hamada, J.-i., additional, Lee, I. Y., additional, Ekram, T., additional, Jain, R., additional, Scarpace, L., additional, Omodon, M., additional, Rock, J., additional, Rosenblum, M., additional, Kalkanis, S., additional, Amankulor, N. M., additional, Kim, J.-H., additional, Tabar, V., additional, Peck, K. K., additional, Holodny, A. I., additional, Gutin, P. H., additional, Kim, C.-Y., additional, Kim, Y.-H., additional, Kim, T., additional, Kim, I. K., additional, Kim, J. W., additional, Kim, Y. H., additional, Han, J. H., additional, Park, C.-K., additional, Kim, D. G., additional, Jung, H.-W., additional, Nonaka, M., additional, Bamba, Y., additional, Kanemura, Y., additional, and Nakajima, S., additional

Published
2012
Full Text
View/download PDF

22. LAB-RADIOBIOLOGY

Author

Floyd, S. R., primary, Pacold, M. E., additional, Clarke, S. M., additional, Blake, E., additional, Fydrych, A., additional, Ho, R., additional, Lee, M. J., additional, Root, D. E., additional, Carpenter, A. E., additional, Sabatini, D. M., additional, French, C. A., additional, Bradner, J. E., additional, Chen, C. C., additional, Yaffe, M. B., additional, Le Rhun, E., additional, Massin, F., additional, Lefevre, A., additional, Bonneterre, J., additional, Bittencourt, M. d. C., additional, Faure, G., additional, Hiramatsu, R., additional, Kawabata, S., additional, Yamada, Y., additional, Miyatake, S.-I., additional, Kuroiwa, T., additional, Li, S., additional, Chou, A. P., additional, Chen, W., additional, Chen, R., additional, Deng, Y., additional, Phillips, H. S., additional, Faull, K. F., additional, Cloughesy, T., additional, Liau, L. M., additional, Lai, A., additional, Mori, K., additional, Ishikura, R., additional, Tomogane, Y., additional, Izumoto, S., additional, Arita, N., additional, Piao, J., additional, Auyeung, G., additional, Policarpio, E., additional, Tabar, V., additional, Yeung, T. P. C., additional, Morrison, L., additional, Hoffman, L., additional, Lee, T.-Y., additional, Bauman, G., additional, Yartsev, S., additional, Ryu, S., additional, Kolozsvary, A., additional, Lapanowski, M., additional, Jenrow, K., additional, Brown, S., additional, Kim, J. H., additional, Brown, R. J., additional, Love, J., additional, Warburton, D., additional, McBride, W., additional, Bluml, S., additional, Ren, X., additional, Vanderwaal, B., additional, Jaboin, J., additional, Baldock, A. L., additional, Anh, S., additional, Rockne, R., additional, Neal, M., additional, Clark-Swanson, K., additional, Sterin, G., additional, Trister, A. D., additional, Malone, H., additional, Ebiana, V., additional, Sonabend, A. M., additional, Mrugala, M., additional, Rockhill, J. K., additional, Silbergeld, D. L., additional, McKhann, G. M., additional, Bruce, J. N., additional, Rostomily, R., additional, Canoll, P., additional, Swanson, K. R., additional, Hawkins-Daarud, A., additional, Baldock, A., additional, Bridge, C., additional, Corwin, D., additional, Mrugala, M. M., additional, Yagle, K., additional, Born, D., additional, and Swanson, P., additional

Published
2012
Full Text
View/download PDF

23. LAB-ANGIOGENESIS AND INVASION

Author

Proescholdt, M. A., primary, Merrill, M. J., additional, Stoerr, E.-M., additional, Lohmeier, A., additional, Brawanski, A., additional, Sim, H., additional, Hu, B., additional, Pineda, C. A., additional, Yoon, S.-O., additional, Viapiano, M. S., additional, Rajappa, P., additional, Cobb, W. S., additional, Huang, Y., additional, Lyden, D. C., additional, Bromberg, J., additional, Greenfield, J. P., additional, Li, M., additional, Mukasa, A., additional, Inda, M. d.-M., additional, Zhang, J., additional, Chin, L., additional, Cavenee, W., additional, Furnari, F., additional, Zheng, P.-P., additional, van der Weiden, M., additional, van der Spek, P. J., additional, Vincent, A. J., additional, Kros, J. M., additional, Fathallah-Shaykh, H. M., additional, Saut, O., additional, Lagaert, J.-B., additional, Colin, T., additional, Araysi, L., additional, Tang, Z., additional, Duck, K. A., additional, Ponnuru, P., additional, Neely, E. B., additional, Connor, J. R., additional, Esencay, M., additional, Gonzalez, P., additional, Gaziel, A., additional, Safraz, Y., additional, Mira, H., additional, Hernando, E., additional, Zagzag, D., additional, McDermott, R. A., additional, Ulasov, I., additional, Kaverina, N., additional, Gabikian, P., additional, Lesniak, M., additional, Iranmahboob, A., additional, Haber, M., additional, Fatterpekar, G., additional, Raz, E., additional, Placantonakis, D., additional, Eoli, M., additional, Rabascio, C., additional, Cuppini, L., additional, Anghileri, E., additional, Pellegatta, S., additional, Calleri, A., additional, Mancuso, P., additional, Porrati, P., additional, Bertolini, F., additional, Finocchiaro, G., additional, Seals, D. F., additional, Burger, K. L., additional, Gibo, D. M., additional, Debinski, W., additional, Tran, N. L., additional, Tuncali, S., additional, Kloss, J., additional, Yang, Z., additional, Schumacher, C. A., additional, Diegel, C., additional, Ross, J. T., additional, Williams, B. O., additional, Eschbacher, J. M., additional, Loftus, J. C., additional, Whiteman, M., additional, Dombovy-Johnson, M., additional, Vangellow, A., additional, Liu, Y., additional, Carson-Walter, E., additional, Walter, K. A., additional, Walter, K., additional, Cortes-Santiago, N., additional, Gabrusiewicz, K., additional, Liu, D., additional, Hossain, M. B., additional, Gumin, J., additional, Fan, X., additional, Conrad, C., additional, Aldape, K., additional, Gilbert, M., additional, Raghunathan, A., additional, Yung, W. K. A., additional, Fueyo, J., additional, Gomez-Manzano, C., additional, Bae, E., additional, Huang, P., additional, Burgett, M., additional, Muller-Greven, G., additional, Kar, N., additional, Gladson, C. L., additional, Engler, J. R., additional, Robinson, A. E., additional, Molinaro, A., additional, Phillips, J. J., additional, Zadeh, G., additional, Burrell, K., additional, Hill, R., additional, Piao, Y., additional, Liang, J., additional, Henry, V., additional, Holmes, L., additional, Sulman, E., additional, deGroot, J. F., additional, de Groot, J. F., additional, Rong, W., additional, Funato, K., additional, Georgala, P., additional, Shimizu, F., additional, Droms, L., additional, Tabar, V., additional, Parker, J. J., additional, Dionne, K. R., additional, Massarwa, R., additional, Klaassen, M., additional, Foreman, N. K., additional, Niswander, L., additional, Canoll, P., additional, Kleinschmidt-DeMasters, B. K., additional, and Waziri, A., additional

Published
2012
Full Text
View/download PDF

24. CLIN-MEDICAL + RADIATION THERAPIES

Author

Kim, J. H., primary, Charkravarti, A., additional, Wang, M., additional, Aldape, K., additional, Sulman, E., additional, Bredel, M., additional, Hegi, M., additional, Gilbert, M., additional, Curran, W., additional, Werner-Wasik, M., additional, Mehta, M., additional, van den Bent, M. J., additional, Brandes, A. A., additional, Taphoorn, M. J., additional, Kros, J. M., additional, Kouwenhoven, M. C., additional, Delattre, J.-Y., additional, Bernsen, H. J., additional, Frenay, M., additional, Tijssen, C. C., additional, Grisold, W., additional, Sipos, L., additional, Enting, R. H., additional, French, P. J., additional, Dinjens, W. N., additional, Vecht, C. J., additional, Allgeier, A., additional, Lacombe, D., additional, Gorlia, T., additional, Xuan, K. H., additional, Chang, J. H., additional, Oh, M. C., additional, Kim, E. H., additional, Kang, S.-G., additional, Cho, J., additional, Kim, S. H., additional, Kim, D. S., additional, Seo, C.-O., additional, Lee, K. S., additional, Kim, M. M., additional, Dabaja, B. S., additional, Jeffrey Medeiros, L., additional, Allen, P., additional, Kim, S., additional, Fowler, N., additional, Peereboom, D. M., additional, Seidman, A. D., additional, Tabar, V., additional, Weil, R. J., additional, Thorsheim, H. R., additional, Smith, Q. R., additional, Lockman, P. R., additional, Steeg, P. S., additional, Mallick, S., additional, Joshi, N., additional, Gandhi, A., additional, Jha, P., additional, Suri, V., additional, Julka, P. K., additional, Sarkar, C., additional, Sharma, D., additional, Rath, G. K., additional, Blumenthal, D. T., additional, Talianski, A., additional, Fishniak, L., additional, Bokstein, F., additional, Taal, W., additional, Walenkamp, A. M., additional, Beerepoot, L., additional, Hanse, M., additional, Buter, J., additional, Honkoop, A., additional, Groenewegen, G., additional, Boerman, D., additional, Jansen, R. L., additional, van den Berkmortel, F. W., additional, Brandsma, D., additional, Bromberg, J. E., additional, van Heuvel, I., additional, Smits, M., additional, van der Holt, B., additional, Vernhout, R., additional, van den Bent, M., additional, Matienzo, L., additional, Batara, J., additional, Torcuator, R., additional, Yovino, S., additional, Balmanoukian, A., additional, Ye, X., additional, Campian, J., additional, Hess, A., additional, Fuchs, E., additional, Grossman, S. A., additional, Leonard, A. K., additional, Wolff, J., additional, Blanchard, M., additional, Laack, N., additional, Foote, R., additional, Brown, P., additional, Pan, E., additional, Yu, D., additional, Yue, B., additional, Potthast, L., additional, Smith, P., additional, Chowdhary, S., additional, Chamberlain, M., additional, Rockhill, J., additional, Sales, L., additional, Halasz, L., additional, Stewart, R., additional, Phillips, M., additional, Mathew, M., additional, Ott, P., additional, Rush, S., additional, Donahue, B., additional, Pavlick, A., additional, Golfinos, J., additional, Parker, E., additional, Huang, P., additional, Narayana, A., additional, Clark, S., additional, Carlson, J. A., additional, Gaspar, L. E., additional, Ney, D. E., additional, Chen, C., additional, Kavanagh, B., additional, Damek, D. M., additional, Martinez, N. L., additional, DeAngelis, L. M., additional, Abrey, L. E., additional, Omuro, A., additional, Zhu, J.-J., additional, Esquenazi-Levy, Y., additional, Friedman, E. R., additional, Tandon, N., additional, Hitchen, C., additional, and Dewyngaert, K., additional

Published
2012
Full Text
View/download PDF

26. Tumor Models (In Vivo/In Vitro)

Author

Doucette, T. A., primary, Kong, L.-Y., additional, Yang, Y., additional, Wei, J., additional, Wang, J., additional, Fuller, G. N., additional, Heimberger, A. B., additional, Rao, G., additional, Ajewung, N., additional, Kamnasaran, D., additional, Katz, A. M., additional, Amankulor, N., additional, Squatrito, M., additional, Hambardzumyan, D., additional, Holland, E. C., additional, Poschl, J., additional, Lorenz, A., additional, Von Bueren, A., additional, Li, S., additional, Peraud, A., additional, Tonn, J.-C., additional, Herms, J., additional, Xiang, M., additional, Rutkowski, S., additional, Kretzschmar, H., additional, Schuller, U., additional, Studebaker, A., additional, Raffel, C., additional, Aoki, Y., additional, Hashizume, R., additional, Ozawa, T., additional, Gupta, N., additional, James, C. D., additional, Navis, A. C., additional, Hamans, B. C., additional, Claes, A., additional, Heerschap, A., additional, Wesseling, P., additional, Jeuken, J. W., additional, Leenders, W. P., additional, Agudelo, P. A., additional, Williams, S., additional, Nowicki, M. O., additional, Johnson, J., additional, Li, P. K., additional, Chiocca, E. A., additional, Lannutti, J. J., additional, Lawler, S. E., additional, Viapiano, M. S., additional, Bergeron, J., additional, Aliaga, A., additional, Bedell, B., additional, Soderquist, C., additional, Sonabend, A., additional, Lei, L., additional, Crisman, C., additional, Yun, J. P., additional, Sisti, J., additional, Castelli, M., additional, Bruce, J. N., additional, Canoll, P., additional, Kirsch, M., additional, Stelling, A., additional, Salzer, R., additional, Krafft, C., additional, Schackert, G., additional, Steiner, G., additional, Balvers, R. K., additional, van den Hengel, S. K., additional, Wakimoto, H., additional, Hoeben, R. C., additional, Leenstra, S., additional, Dirven, C. M., additional, Lamfers, M. L., additional, Sabha, N. S., additional, Agnihotri, S., additional, Wolf, A., additional, von Deimling, A., additional, Croul, S., additional, Guha, A., additional, Trojahn, U. S., additional, Lenferink, A., additional, O'Connor-McCourt, M., additional, Kanai, R., additional, Curry, W. T., additional, Yip, S., additional, Barnard, Z. R., additional, Mohapatra, G., additional, Stemmer-Rachamimov, A. O., additional, Martuza, R. L., additional, Rabkin, S. D., additional, Binder, Z. A., additional, Salmasi, V., additional, Lim, M., additional, Weingart, J., additional, Brem, H., additional, Olivi, A., additional, Riggins, G. J., additional, Gallia, G. L., additional, Rong, Y., additional, Zhang, Z., additional, Gang, C., additional, Tucker-Burden, C., additional, Van Meir, E., additional, Brat, D. J., additional, Kloezeman, J. J., additional, Kleijn, A., additional, French, P. J., additional, Spoor, J. K., additional, Bazzoli, E., additional, Fomchenko, E. I., additional, Schultz, N., additional, Brennan, C., additional, DeAngelis, L. M., additional, Nimer, S. D., additional, Mohyeldin, A., additional, Hsu, W., additional, Shah, S. R., additional, Adams, H., additional, Shah, P., additional, Katuri, L., additional, Kosztowski, T., additional, Loeb, D. M., additional, Wolinsky, J.-P., additional, Gokaskan, Z. L., additional, Quinones-Hinojosa, A., additional, Daphu, I. K., additional, Immervoll, H., additional, Bjerkvig, R., additional, Thorsen, F., additional, Caretti, V., additional, Idema, S., additional, Zondervan, I., additional, Meijer, D. H., additional, Lagerweij, T., additional, Barazas, M., additional, Vos, W., additional, Hamans, B., additional, van der Stoop, P., additional, Hulleman, E., additional, van der Valk, P., additional, Bugiani, M., additional, Vandertop, W. P., additional, Noske, D., additional, Kaspers, G. J., additional, Molthoff, C., additional, Wurdinger, T., additional, Chow, L. M., additional, Endersby, R., additional, Zhu, X., additional, Rankin, S., additional, Qu, C., additional, Zhang, J., additional, Ellison, D. W., additional, Baker, S. J., additional, Tabar, V., additional, LaFaille, F., additional, and Studer, L., additional

Published
2010
Full Text
View/download PDF

38. The molecular landscape of glioma in patients with Neurofibromatosis 1

Author

Dominique Vidaud, Mariona Suñol, Tala, Francesco DiMeco, John de Groot, Gaetano Finocchiaro, Fulvio D'Angelo, Luc Bauchet, Marica Eoli, Véronique Lorgis, David Meyronet, Kristin Alfaro, Luciano Garofano, John M. Slopis, Laurent Capelle, Pascale Varlet, Giulia Berzero, Mario Cangiano, Veronica Saletti, Romuald Seizeur, Jing Zhang, Carlo Efisio Marras, Veronique Frattini, Walid Farah, Cinzia Lavarino, David Cachia, Genevieve Lewis, Michele Ceccarelli, Seung-Ki Kim, David E. Reuss, Hugues Loiseau, Carlos Kamiya-Matsuoka, Do-Hyun Nam, Krishna P. Bhat, Stéphane Goutagny, Karima Mokhtari, François Ducray, Anna Lasorella, Colin Watts, Francesca Pia Caruso, Hector Salvador, Antonio Iavarone, F. Vandenbos, Ian E. McCutcheon, Susanna Ronchi, Viviane Tabar, Marc Sanson, D'Angelo, Fulvio, Ceccarelli, Michele, Tala, Garofano, Luciano, Zhang, Jing, Frattini, Veronique, Caruso, Francesca P., Lewis, Genevieve, Alfaro, Kristin D., Bauchet, Luc, Berzero, Giulia, Cachia, David, Cangiano, Mario, Capelle, Laurent, de Groot, John, Dimeco, Francesco, Ducray, Francoi, Farah, Walid, Finocchiaro, Gaetano, Goutagny, Stephane, Kamiya-Matsuoka, Carlo, Lavarino, Cinzia, Loiseau, Hugue, Lorgis, Veronique, Marras, Carlo E., Mccutcheon, Ian, Nam, Do-Hyun, Ronchi, Susanna, Saletti, Veronica, Seizeur, Romuald, Slopis, John, Sunol, Mariona, Vandenbos, Fanny, Varlet, Pascale, Vidaud, Dominique, Watts, Colin, Tabar, Viviane, Reuss, David E., Kim, Seung-Ki, Meyronet, David, Mokhtari, Karima, Salvador, Hector, Bhat, Krishna P., Eoli, Marica, Sanson, Marc, Lasorella, Anna, Iavarone, Antonio, D'Angelo, F., Ceccarelli, M., Garofano, L., Zhang, J., Frattini, V., Caruso, F. P., Lewis, G., Alfaro, K. D., Bauchet, L., Berzero, G., Cachia, D., Cangiano, M., Capelle, L., de Groot, J., Dimeco, F., Ducray, F., Farah, W., Finocchiaro, G., Goutagny, S., Kamiya-Matsuoka, C., Lavarino, C., Loiseau, H., Lorgis, V., Marras, C. E., Mccutcheon, I., Nam, D. -H., Ronchi, S., Saletti, V., Seizeur, R., Slopis, J., Sunol, M., Vandenbos, F., Varlet, P., Vidaud, D., Watts, C., Tabar, V., Reuss, D. E., Kim, S. -K., Meyronet, D., Mokhtari, K., Salvador, H., Bhat, K. P., Eoli, M., Sanson, M., Lasorella, A., Iavarone, A., Columbia University Medical Center (CUMC), Columbia University [New York], University of Sannio [Benevento], The University of Texas M.D. Anderson Cancer Center [Houston], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Medical University of South Carolina [Charleston] (MUSC), Service de Neurochirurgie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Fondazione IRCCS Istituto Neurologico 'Carlo Besta', University of Milan, Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de neurochirurgie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Bordeaux [Bordeaux], Département d'oncologie médicale [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Sungkyunkwan University [Suwon] (SKKU), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Pasteur [Nice] (CHU), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Sainte Anne [Paris], Génétique, physiopathologie et approches thérapeutiques des maladies héréditaires du système nerveux (EA 7331), Université Paris Descartes - Paris 5 (UPD5), Hôpital Cochin [AP-HP], University of Birmingham [Birmingham], Memorial Sloane Kettering Cancer Center [New York], German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Heidelberg University, Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Beaujon, Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), and CHU Cochin [AP-HP]

Subjects
0301 basic medicine, Adult, Male, congenital, hereditary, and neonatal diseases and abnormalities, X-linked Nuclear Protein, Neurofibromatosis 1, Adolescent, [SDV]Life Sciences [q-bio], T-Lymphocytes, Biology, General Biochemistry, Genetics and Molecular Biology, Article, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Germline mutation, CDKN2A, Antigens, Neoplasm, Glioma, medicine, Humans, Epigenetics, Neurofibromatosis, 10. No inequality, Child, Gene, neoplasms, ATRX, Germ-Line Mutation, Cancer, Neurofibromin 1, Brain Neoplasms, Reproducibility of Results, General Medicine, DNA Methylation, Middle Aged, medicine.disease, 3. Good health, nervous system diseases, 030104 developmental biology, 030220 oncology & carcinogenesis, Child, Preschool, DNA methylation, Cancer research, Genomics, Bioinformatic, Female, Transcriptome
Abstract

Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome in which glioma is one of the prevalent tumors. Gliomagenesis in NF1 results in a heterogeneous spectrum of low- to high-grade neoplasms occurring during the entire lifespan of patients. The pattern of genetic and epigenetic alterations of glioma that develops in NF1 patients and the similarities with sporadic glioma remain unknown. Here, we present the molecular landscape of low- and high-grade gliomas in patients affected by NF1 (NF1-glioma). We found that the predisposing germline mutation of the NF1 gene was frequently converted to homozygosity and the somatic mutational load of NF1-glioma was influenced by age and grade. High-grade tumors harbored genetic alterations of TP53 and CDKN2A, frequent mutations of ATRX associated with Alternative Lengthening of Telomere, and were enriched in genetic alterations of transcription/chromatin regulation and PI3 kinase pathways. Low-grade tumors exhibited fewer mutations that were over-represented in genes of the MAP kinase pathway. Approximately 50% of low-grade NF1-gliomas displayed an immune signature, T lymphocyte infiltrates, and increased neo-antigen load. DNA methylation assigned NF1-glioma to LGm6, a poorly defined Isocitrate Dehydrogenase 1 wild-type subgroup enriched with ATRX mutations. Thus, the profiling of NF1-glioma defined a distinct landscape that recapitulates a subset of sporadic tumors. An integrated analysis of glioma samples from patients with neurofibromatosis 1 annotates their mutational, epigenetic, transcriptional, and immunological features and uncovers similitudes with a subset of sporadic gliomas.

Published
2018

39. Sleep disruption in patients with active and treated endogenous Cushing's syndrome.

Author

Geer EB, Grillo I, Li Q, Robins H, Cohen V, Baratz H, Garcia C, Sazo M, Lin A, Cohen M, Tabar V, Mao J, and Garland SN

Abstract

Context: The hypothalamic-pituitary-adrenal axis is a critical regulator of circadian rhythm in humans. Impaired sleep adversely affects metabolic, emotional, and cognitive health., Objective: To characterize sleep disturbances in patients with active and treated Cushing's syndrome (CS), and identify factors associated with impaired sleep in treated patients., Design: Single-center cross-sectional study., Methods: Patients with pituitary or adrenal CS enrolled in an observational study completed Nottingham Health Profile (NHP), CushingQoL, and Hospital Anxiety and Depression assessments. Cross-sectional analysis was conducted including patients with active and treated disease., Results: 113 (94 female) patients with CS were included, 104 pituitary and 9 adrenal, with mean age at diagnosis of 43.9 ± 13.4 years. Mean and maximum duration of follow up was 5.1 and 23 years. Mean NHP sleep score was lower (i.e., improved) in patients with treated vs. active disease (29.6 ± 30.2 vs. 51.9 ± 30.9, p = 0.0005), as was CushingQoL sleep score (p = 0.015), but 41.5% of patients with treated disease stated they often or always had trouble sleeping. The proportion of treated vs. active patients taking medication for sleep, mood, or pain was not different. Neither NHP nor CushingQoL pain scores were lower in treated vs. active patients (p = 0.39 and 0.53). In patients with treated CS, anxiety and depression correlated with worse sleep scores., Conclusions: Patients with treated CS report improved sleep quality compared to those with active disease, but almost half of treated patients still report sleep challenges. The need for sleep medications, reported by one third of patients, was not different after CS treatment. Ongoing mood disturbances may play a role in persistent sleep disruption. Further work should focus on determinants of sleep impairments in treated CS patients., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

40. Single-cell atlas of the human brain vasculature across development, adulthood and disease.

Author

Wälchli T, Ghobrial M, Schwab M, Takada S, Zhong H, Suntharalingham S, Vetiska S, Gonzalez DR, Wu R, Rehrauer H, Dinesh A, Yu K, Chen ELY, Bisschop J, Farnhammer F, Mansur A, Kalucka J, Tirosh I, Regli L, Schaller K, Frei K, Ketela T, Bernstein M, Kongkham P, Carmeliet P, Valiante T, Dirks PB, Suva ML, Zadeh G, Tabar V, Schlapbach R, Jackson HW, De Bock K, Fish JE, Monnier PP, Bader GD, and Radovanovic I

Subjects
Female, Humans, Male, Cell Communication, HLA-D Antigens metabolism, Adult, Health, Brain blood supply, Brain pathology, Brain embryology, Brain metabolism, Brain Neoplasms blood supply, Brain Neoplasms pathology, Endothelial Cells metabolism, Endothelial Cells pathology, Endothelial Cells cytology, Fetus blood supply, Fetus cytology, Fetus embryology, RNA-Seq, Single-Cell Gene Expression Analysis, Central Nervous System Vascular Malformations pathology
Abstract

A broad range of brain pathologies critically relies on the vasculature, and cerebrovascular disease is a leading cause of death worldwide. However, the cellular and molecular architecture of the human brain vasculature remains incompletely understood 1 . Here we performed single-cell RNA sequencing analysis of 606,380 freshly isolated endothelial cells, perivascular cells and other tissue-derived cells from 117 samples, from 68 human fetuses and adult patients to construct a molecular atlas of the developing fetal, adult control and diseased human brain vasculature. We identify extensive molecular heterogeneity of the vasculature of healthy fetal and adult human brains and across five vascular-dependent central nervous system (CNS) pathologies, including brain tumours and brain vascular malformations. We identify alteration of arteriovenous differentiation and reactivated fetal as well as conserved dysregulated genes and pathways in the diseased vasculature. Pathological endothelial cells display a loss of CNS-specific properties and reveal an upregulation of MHC class II molecules, indicating atypical features of CNS endothelial cells. Cell-cell interaction analyses predict substantial endothelial-to-perivascular cell ligand-receptor cross-talk, including immune-related and angiogenic pathways, thereby revealing a central role for the endothelium within brain neurovascular unit signalling networks. Our single-cell brain atlas provides insights into the molecular architecture and heterogeneity of the developing, adult/control and diseased human brain vasculature and serves as a powerful reference for future studies., (© 2024. Crown.)

Published
2024
Full Text
View/download PDF

41. Mechanism of neurodegeneration mediated by clonal inflammatory microglia.

Author

Vicario R, Fragkogianni S, Pokrovskii M, Mayer C, Lopez-Rodrigo E, Hu Y, Ogishi M, Alberdi A, Baako A, Ay O, Plu I, Sazdovitch V, Heritier S, Cohen-Aubart F, Shor N, Miyara M, Nguyen-Khac F, Viale A, Idbaih A, Amoura Z, Rosenblum MK, Zhang H, Karnoub ER, Sashittal P, Jakatdar A, Iacobuzio-Donahue CA, Abdel-Wahab O, Tabar V, Socci ND, Elemento O, Diamond EL, Boisson B, Casanova JL, Seilhean D, Haroche J, Donadieu J, and Geissmann F

Abstract

Langerhans cell Histiocytosis (LCH) and Erdheim-Chester disease (ECD) are clonal myeloid disorders, associated with MAP-Kinase activating mutations and an increased risk of neurodegeneration. Surprisingly, we found pervasive PU.1 + microglia mutant clones across the brain of LCH and ECD patients with and without neurological symptoms, associated with microgliosis, reactive astrocytosis, and neuronal loss. The disease predominated in the grey nuclei of the rhombencephalon, a topography attributable to a local proliferative advantage of mutant microglia. Presence of clinical symptoms was associated with a longer evolution of the disease and a larger size of PU.1 + clones (p= 0.0003). Genetic lineage tracing of PU.1 + clones suggest a resident macrophage lineage or a bone marrow precursor origin depending on patients. Finally, a CSF1R-inhibitor depleted mutant microglia and limited neuronal loss in mice suggesting an alternative to MAPK inhibitors. These studies characterize a progressive neurodegenerative disease, caused by clonal proliferation of inflammatory microglia (CPIM), with a decade(s)-long preclinical stage of incipient disease that represent a therapeutic window for prevention of neuronal death., Competing Interests: Conflict of Interest. FG has performed consulting for Third Rock venture in the past. Targeted Sequencing was funded in part by a grant from Third Rock venture. FG and RV are inventors in MSKCC’s United States application or PCT international application number PCT/US2018/047964 filed on 8/24/2018 (KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERS)

Published
2024
Full Text
View/download PDF

42. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.

Author

Lin AL, Rudneva VA, Richards AL, Zhang Y, Woo HJ, Cohen M, Tisnado J, Majd N, Wardlaw SL, Page-Wilson G, Sengupta S, Chow F, Goichot B, Ozer BH, Dietrich J, Nachtigall L, Desai A, Alano T, Ogilive S, Solit DB, Bale TA, Rosenblum M, Donoghue MTA, Geer EB, and Tabar V

Subjects
Humans, Male, Female, Middle Aged, Adult, Aged, Retrospective Studies, Mutation genetics, Prospective Studies, Loss of Heterozygosity genetics, Pituitary Neoplasms genetics, Pituitary Neoplasms pathology, Neuroendocrine Tumors genetics, Neuroendocrine Tumors pathology, Neuroendocrine Tumors therapy
Abstract

Pituitary neuroendocrine tumors (PitNETs) exhibiting aggressive, treatment-refractory behavior are the rare subset that progress after surgery, conventional medical therapies, and an initial course of radiation and are characterized by unrelenting growth and/or metastatic dissemination. Two groups of patients with PitNETs were sequenced: a prospective group of patients (n = 66) who consented to sequencing prior to surgery and a retrospective group (n = 26) comprised of aggressive/higher risk PitNETs. A higher mutational burden and fraction of loss of heterozygosity (LOH) was found in the aggressive, treatment-refractory PitNETs compared to the benign tumors (p = 1.3 × 10 -10 and p = 8.5 × 10 -9 , respectively). Within the corticotroph lineage, a characteristic pattern of recurrent chromosomal LOH in 12 specific chromosomes was associated with treatment-refractoriness (occurring in 11 of 14 treatment-refractory versus 1 of 14 benign corticotroph PitNETs, p = 1.7 × 10 -4 ). Across the cohort, a higher fraction of LOH was identified in tumors with TP53 mutations (p = 3.3 × 10 -8 ). A machine learning approach identified loss of heterozygosity as the most predictive variable for aggressive, treatment-refractory behavior, outperforming the most common gene-level alteration, TP53, with an accuracy of 0.88 (95% CI: 0.70-0.96). Aggressive, treatment-refractory PitNETs are characterized by significant aneuploidy due to widespread chromosomal LOH, most prominently in the corticotroph tumors. This LOH predicts treatment-refractoriness with high accuracy and represents a novel biomarker for this poorly defined PitNET category., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

43. Different patient versus provider perspectives on living with Cushing's disease.

Author

Halstrom A, Lin IH, Lin A, Cohen M, Tabar V, and Geer EB

Subjects
Humans, Female, Middle Aged, Male, Quality of Life psychology, Longitudinal Studies, Motivation, Pituitary ACTH Hypersecretion therapy, Pituitary ACTH Hypersecretion diagnosis, Neoplasms
Abstract

Context: Patients with Cushing's disease (CD) face challenges living with and receiving appropriate care for this rare, chronic condition. Even with successful treatment, many patients experience ongoing symptoms and impaired quality of life (QoL). Different perspectives and expectations between patients and healthcare providers (HCPs) may also impair well-being., Objective: To examine differences in perspectives on living with CD between patients and HCPs, and to compare care goals and unmet needs., Design: Memorial Sloan Kettering Pituitary Center established an annual pituitary symposium for pituitary patients and HCPs. Through anonymous pre-program surveys distributed at the 2020 and 2022 symposia, patients and HCPs answered questions related to their own sense, or perception of their patients' sense, of hope, choice, and loneliness in the context of living with CD., Participants: From 655 participants over two educational events, 46 patients with CD and 116 HCPs were included. Median age of both groups was 51 years. 78.3% of the patients were female vs. 53.0% of the HCPs., Results: More patients than HCPs reported they had no choices in their treatment (21.7% vs. 0.9%, P < 0.001). More patients reported feeling alone living with CD than HCPs' perception of such (60.9% vs. 45.5%, P = 0.08). The most common personal care goal concern for patients was 'QoL/mental health,' vs. 'medical therapies/tumor control' for HCPs. The most common CD unmet need reported by patients was 'education/awareness' vs. 'medical therapies/tumor control' for HCPs., Conclusions: CD patients experience long term symptoms and impaired QoL which may in part be due to a perception of lack of effective treatment options and little hope for improvement. Communicating experiences and care goals may improve long term outcomes for CD patients., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

44. Transcript-specific enrichment enables profiling rare cell states via scRNA-seq.

Author

Abay T, Stickels RR, Takizawa MT, Nalbant BN, Hsieh YH, Hwang S, Snopkowski C, Yu KKH, Abou-Mrad Z, Tabar V, Ludwig LS, Chaligné R, Satpathy AT, and Lareau CA

Abstract

Single-cell genomics technologies have accelerated our understanding of cell-state heterogeneity in diverse contexts. Although single-cell RNA sequencing (scRNA-seq) identifies many rare populations of interest that express specific marker transcript combinations, traditional flow sorting limits our ability to enrich these populations for further profiling, including requiring cell surface markers with high-fidelity antibodies. Additionally, many single-cell studies require the isolation of nuclei from tissue, eliminating the ability to enrich learned rare cell states based on extranuclear protein markers. To address these limitations, we describe Programmable Enrichment via RNA Flow-FISH by sequencing (PERFF-seq), a scalable assay that enables scRNA-seq profiling of subpopulations from complex cellular mixtures defined by the presence or absence of specific RNA transcripts. Across immune populations ( n = 141,227 cells) and fresh-frozen and formalin-fixed paraffin-embedded brain tissue ( n = 29,522 nuclei), we demonstrate the sorting logic that can be used to enrich for cell populations via RNA-based cytometry followed by high-throughput scRNA-seq. Our approach provides a rational, programmable method for studying rare populations identified by one or more marker transcripts., Competing Interests: Competing interests A.T.S. is a founder of Immunai, Cartography Biosciences, and Prox Biosciences, an advisor to Zafrens, Pallando Therapeutics, and Wing Venture Capital, and receives research funding from Merck Research Laboratories. R.R.S., L.S.L., and C.A.L. are consultants to Cartography Biosciences. R.C. is a consultant for Sanavia Oncology, S2 Genomics, and LevitasBio.

Published
2024
Full Text
View/download PDF

45. Development and prospective validation of an artificial intelligence-based smartphone app for rapid intraoperative pituitary adenoma identification.

Author

Bou-Nassif R, Reiner AS, Pease M, Bale T, Cohen MA, Rosenblum M, and Tabar V

Abstract

Background: Intraoperative pathology consultation plays a crucial role in tumor surgery. The ability to accurately and rapidly distinguish tumor from normal tissue can greatly impact intraoperative surgical oncology management. However, this is dependent on the availability of a specialized pathologist for a reliable diagnosis. We developed and prospectively validated an artificial intelligence-based smartphone app capable of differentiating between pituitary adenoma and normal pituitary gland using stimulated Raman histology, almost instantly., Methods: The study consisted of three parts. After data collection (part 1) and development of a deep learning-based smartphone app (part 2), we conducted a prospective study that included 40 consecutive patients with 194 samples to evaluate the app in real-time in a surgical setting (part 3). The smartphone app's sensitivity, specificity, positive predictive value, and negative predictive value were evaluated by comparing the diagnosis rendered by the app to the ground-truth diagnosis set by a neuropathologist., Results: The app exhibits a sensitivity of 96.1% (95% CI: 89.9-99.0%), specificity of 92.7% (95% CI: 74-99.3%), positive predictive value of 98% (95% CI: 92.2-99.8%), and negative predictive value of 86.4% (95% CI: 66.2-96.8%). An external validation of the smartphone app on 40 different adenoma tumors and a total of 191 scanned SRH specimens from a public database shows a sensitivity of 93.7% (95% CI: 89.3-96.7%)., Conclusions: The app can be readily expanded and repurposed to work on different types of tumors and optical images. Rapid recognition of normal versus tumor tissue during surgery may contribute to improved intraoperative surgical management and oncologic outcomes. In addition to the accelerated pathological assessments during surgery, this platform can be of great benefit in community hospitals and developing countries, where immediate access to a specialized pathologist during surgery is limited., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

46. NOVA1 acts as an oncogenic RNA-binding protein to regulate cholesterol homeostasis in human glioblastoma cells.

Author

Saito Y, Yang Y, Saito M, Park CY, Funato K, Tabar V, and Darnell RB

Subjects
Humans, RNA-Binding Proteins genetics, RNA-Binding Proteins metabolism, Homeostasis genetics, Cholesterol, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Neuro-Oncological Ventral Antigen, Glioblastoma genetics, Glioblastoma metabolism, MicroRNAs genetics
Abstract

NOVA1 is a neuronal RNA-binding protein identified as the target antigen of a rare autoimmune disorder associated with cancer and neurological symptoms, termed paraneoplastic opsoclonus-myoclonus ataxia. Despite the strong association between NOVA1 and cancer, it has been unclear how NOVA1 function might contribute to cancer biology. In this study, we find that NOVA1 acts as an oncogenic factor in a GBM (glioblastoma multiforme) cell line established from a patient. Interestingly, NOVA1 and Argonaute (AGO) CLIP identified common 3' untranslated region (UTR) targets, which were down-regulated in NOVA1 knockdown GBM cells, indicating a transcriptome-wide intersection of NOVA1 and AGO-microRNA (miRNA) targets regulation. NOVA1 binding to 3'UTR targets stabilized transcripts including those encoding cholesterol homeostasis related proteins. Selective inhibition of NOVA1-RNA interactions with antisense oligonucleotides disrupted GBM cancer cell fitness. The precision of our GBM CLIP studies point to both mechanism and precise RNA sequence sites to selectively inhibit oncogenic NOVA1-RNA interactions. Taken together, we find that NOVA1 is commonly overexpressed in GBM, where it can antagonize AGO2-miRNA actions and consequently up-regulates cholesterol synthesis, promoting cell viability., Competing Interests: Competing interests statement:R.B.D. is a consultant for Atreca, Inc. and OPNA IO, LLC, and is a founder of a nonprofit (Permantis Public Health) for which he has no financial stake.

Published
2024
Full Text
View/download PDF

47. Sham surgery for the trialing of cell-based therapies to the CNS may not be necessary.

Author

Tabar V and Barker RA

Subjects
Humans, Dopaminergic Neurons, Randomized Controlled Trials as Topic, Cell- and Tissue-Based Therapy, Parkinson Disease therapy
Abstract

Sham surgery is often required for cell therapies adopting a randomized placebo-controlled double-blinded trial design. Using the case of dopamine neuron therapy for Parkinson's disease, we argue that alternative trial designs should be considered instead, for several reasons relating to ethics, patient burden, ease of unblinding, and cost., Competing Interests: Declaration of interests V.T. is a co-founder, advisor, and recipient of research support from BlueRock Therapeutics. R.A.B. is a consultant for NovoNordisk, Aspen Neuroscience, Bayer, Transine Therapeutics, Rinri Therapeutics, and UCB on patient-related outcome measures., (Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

48. Investigative needle core biopsies for multi-omics in Glioblastoma.

Author

Yu KKH, Basu S, Baquer G, Ahn R, Gantchev J, Jindal S, Regan MS, Abou-Mrad Z, Prabhu MC, Williams MJ, D'Souza AD, Malinowski SW, Hopland K, Elhanati Y, Stopka SA, Stortchevoi A, He Z, Sun J, Chen Y, Espejo AB, Chow KH, Yerrum S, Kao PL, Kerrigan BP, Norberg L, Nielsen D, Puduvalli VK, Huse J, Beroukhim R, Kim YSB, Goswami S, Boire A, Frisken S, Cima MJ, Holdhoff M, Lucas CG, Bettegowda C, Levine SS, Bale TA, Brennan C, Reardon DA, Lang FF, Antonio Chiocca E, Ligon KL, White FM, Sharma P, Tabar V, and Agar NYR

Abstract

Glioblastoma (GBM) is a primary brain cancer with an abysmal prognosis and few effective therapies. The ability to investigate the tumor microenvironment before and during treatment would greatly enhance both understanding of disease response and progression, as well as the delivery and impact of therapeutics. Stereotactic biopsies are a routine surgical procedure performed primarily for diagnostic histopathologic purposes. The role of investigative biopsies - tissue sampling for the purpose of understanding tumor microenvironmental responses to treatment using integrated multi-modal molecular analyses ('Multi-omics") has yet to be defined. Secondly, it is unknown whether comparatively small tissue samples from brain biopsies can yield sufficient information with such methods. Here we adapt stereotactic needle core biopsy tissue in two separate patients. In the first patient with recurrent GBM we performed highly resolved multi-omics analysis methods including single cell RNA sequencing, spatial-transcriptomics, metabolomics, proteomics, phosphoproteomics, T-cell clonotype analysis, and MHC Class I immunopeptidomics from biopsy tissue that was obtained from a single procedure. In a second patient we analyzed multi-regional core biopsies to decipher spatial and genomic variance. We also investigated the utility of stereotactic biopsies as a method for generating patient derived xenograft models in a separate patient cohort. Dataset integration across modalities showed good correspondence between spatial modalities, highlighted immune cell associated metabolic pathways and revealed poor correlation between RNA expression and the tumor MHC Class I immunopeptidome. In conclusion, stereotactic needle biopsy cores are of sufficient quality to generate multi-omics data, provide data rich insight into a patient's disease process and tumor immune microenvironment and can be of value in evaluating treatment responses., One Sentence Summary: Integrative multi-omics analysis of stereotactic needle core biopsies in glioblastoma.

Published
2023
Full Text
View/download PDF

49. Association of Lack of Speech Arrest During Cortical Stimulation With Interhemispheric Reorganization of the Functional Language Network in Patients With Brain Tumors.

Author

Pasquini L, Tao A, Ferraro GD, Jenabi M, Peck KK, Napolitano A, Fahy TA, Brennan C, Moss NS, Tabar V, Makse H, and Holodny AI

Subjects
Humans, Infant, Newborn, Speech physiology, Retrospective Studies, Wakefulness, Magnetic Resonance Imaging, Language, Brain Mapping methods, Brain Neoplasms diagnostic imaging, Brain Neoplasms surgery, Brain Neoplasms pathology
Abstract

BACKGROUND. Brain tumors induce language reorganization, which may influence the extent of resection in surgical planning. Direct cortical stimulation (DCS) allows definitive language mapping during awake surgery by locating areas of speech arrest (SA) surrounding the tumor. Although functional MRI (fMRI) combined with graph theory analysis can illustrate whole-brain network reorganization, few studies have corroborated these findings with DCS intraoperative mapping and clinical language performance. OBJECTIVE. We evaluated whether patients with low-grade gliomas (LGGs) without SA during DCS show increased right-hemispheric connections and better speech performance compared with patients with SA. METHODS. We retrospectively recruited 44 consecutive patients with left perisylvian LGG, preoperative language task-based fMRI, speech performance evaluation, and awake surgery with DCS. We generated language networks from ROIs corresponding to known language areas (i.e., language core) on fMRI using optimal percolation. Language core connectivity in the left and right hemispheres was quantified as fMRI laterality index (LI) and connectivity LI on the basis of fMRI activation maps and connectivity matrices. We compared fMRI LI and connectivity LI between patients with SA and without SA and used multivariable logistic regression ( p < .05) to assess associations between DCS and connectivity LI, fMRI LI, tumor location, Broca area and Wernicke area involvement, prior treatments, age, handedness, sex, tumor size, and speech deficit before surgery, within 1 week after surgery, and 3-6 months after surgery. RESULTS. Patients with SA showed left-dominant connectivity; patients without SA lateralized more to the right hemisphere ( p < .001). Between patients with SA and those without, fMRI LI was not significantly different. Patients without SA showed right-greater-than-left connectivity of Broca area and premotor area compared with patients with SA. Regression analysis showed significant association between no SA and right-lateralized connectivity LI ( p < .001) and fewer speech deficits before ( p < .001) and 1 week after ( p = .02) surgery. CONCLUSION. Patients without SA had increased right-hemispheric connections and right translocation of the language core, suggesting language reorganization. Lack of interoperative SA was associated with fewer speech deficits both before and immediately after surgery. CLINICAL IMPACT. These findings support tumor-induced language plasticity as a compensatory mechanism, which may lead to fewer postsurgical deficits and allow extended resection.

Published
2023
Full Text
View/download PDF

50. Virtual Surgical Planning and Three-Dimensional Models for Precision Sinonasal and Skull Base Surgery.

Author

Fitzgerald CW, Hararah M, Mclean T, Woods R, Dogan S, Tabar V, Ganly I, Matros E, and Cohen MA

Abstract

Sinonasal and skull base malignancies represent a rare, heterogenous group of pathologies with an incidence of 0.556 per 100,000 persons in the population. Given the numerous critical anatomic structures located adjacent to the sinonasal cavity and skull base, surgery for tumors in this region requires careful pre-operative planning with the assistance of radiological imaging and intraoperative image guidance technologies to reduce the risk of complications. Virtual surgical planning (VSP) and three-dimensional models (3DMs) are adjunctive technologies which assist clinicians to better visualize patient anatomy using enhanced digital radiological images and physical stereolithographic models based on patients' personal imaging. This review summarizes our institutional experience with VSP and 3DMs in sinonasal and skull base surgical oncology. A clinical case series is used to thematically illustrate the application of VSP and 3DMs in surgical ablation, reconstruction, patient communication, medical education, and interdisciplinary teamwork in sinonasal and skull base surgery.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results